Tested drug for acute ischemic stroke within 24 hours
Part of Brain & nervous system, Heart & circulation clinical trials.
This Phase 3 trial studies sovateltide (and a placebo) in adults with an ischemic stroke, aiming to improve safety and outcomes. It focuses on people who can start treatment quickly after stroke symptoms begin and who do not have bleeding in the brain on imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 80 years old
- Have an ischemic stroke (a blood-flow blockage), confirmed by CT or MRI, with NO bleeding seen on the scan
- Be able to start the first dose within 24 hours of when symptoms began (or last seen normal, if symptoms were during sleep)
- Have moderate stroke severity on screening (NIHSS score at least 8 but less than 20, and consciousness level not too impaired)
- Be able to attend the full treatment course and follow-up visits
- Be willing and able to give consent (as required by local laws and the study’s ethics rules)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
This Phase 2 trial tests whether the study medicine (LT3001) is safe and improves outcomes for people with an acute ischemic stroke who are getting a procedure to remove a clot (EVT). It aims to help certain patients who have a specific brain scan pattern soon after stroke symptoms start.
This trial tests if a clot-dissolving medicine can help people who had a mild ischemic stroke and also had a prior stroke in the last 3 months. It aims to see if the treatment is safe and effective for this specific group.
This trial tests whether adding a medication called sivelestat sodium to emergency clot removal surgery (mechanical thrombectomy) can improve outcomes in patients with a specific type of stroke caused by a large blood clot in the front part of the brain. The goal is to see if this combination treatment leads to better recovery.
This trial tests if a medication called tirofiban can help people who had a stroke 4.5 to 24 hours ago and received clot-dissolving treatment (IVT). If you have had a stroke and your symptoms did not improve or got worse after IVT, this study might offer a way to prevent further disability.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.